MWNA
INSY

Marshall Wace North America’s Insys Therapeutics, Inc. INSY Stock Holding History

Marshall Wace North America’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,630
Closed -$102K – 1831
2017
Q4 		$102K Buy
+10,630
New +$69.6K ﹤0.01% 1314
2017
Q3 		– Sell
-47,096
Closed -$612K – 1643
2017
Q2 		$612K Buy
+47,096
New +$557K ﹤0.01% 1056

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Marshall Wace North America's INSY Position: Q1 2018 in Review

Marshall Wace North America sold out of Insys Therapeutics, Inc. (INSY) in Q1 2018, closing a stake of 10,630 shares — an estimated $102K sold.

Marshall Wace North America first reported a position in INSY in Q2 2017 and held it in 2 quarters. The position peaked at $612K in Q2 2017. 110 funds tracked by Wall St. Rank hold INSY as of Q1 2018.

  • Marshall Wace North America reported no remaining Insys Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Marshall Wace North America sold 10,630 Insys Therapeutics, Inc. shares in Q1 2018, an estimated $102K.
  • Marshall Wace North America first reported a position in Insys Therapeutics, Inc. in Q2 2017 and held it in 2 quarters.
  • Marshall Wace North America's Insys Therapeutics, Inc. position peaked at $612K in Q2 2017.
  • 110 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2018.

Based on Marshall Wace North America's 13F filing for Q1 2018, filed 15 May 2018.